FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1. **Name and Address of Company**

MedReleaf Corp. (“**MedReleaf**”)
Markham Industrial Park
Markham, Ontario
Canada L3R 6G3

Item 2. **Date of Material Change**

July 25, 2018

Item 3. **News Release**

A news release with respect to the material change referred to in this report was issued in Canada through the facilities of Canada Newswire and filed on SEDAR on July 25, 2018.

Item 4. **Summary of Material Change**

On July 25, 2018, MedReleaf completed its previously announced plan of arrangement (the “**Arrangement**”) pursuant to an arrangement agreement dated May 14, 2018, as amended by an amending agreement dated May 24, 2018 (the “**Arrangement Agreement**”) with Aurora Cannabis Inc. (“**Aurora**”), whereby Aurora acquired all of MedReleaf’s issued and outstanding common shares for 3.575 common shares of Aurora and $0.000001 in cash for each MedReleaf common share held.

Item 5. **Full Description of Material Change**

5.1 Full Description of Material Change

On July 25, 2018, MedReleaf and Aurora completed the Arrangement. The Arrangement was approved by shareholders of MedReleaf at the special meeting of shareholders held on July 18, 2018. Pursuant to the terms of the Arrangement Agreement, Aurora has acquired all of the issued and outstanding common shares of MedReleaf for 3.575 common shares of Aurora and $0.000001 in cash for each MedReleaf common share held. Taxable Canadian resident MedReleaf shareholders were entitled to elect to receive tax-deferred roll-over treatment in connection with the acquisition by Aurora of their MedReleaf shares. Further information regarding the Arrangement is available in the management information circular of MedReleaf dated June 18, 2018 provided to MedReleaf shareholders in connection with the special meeting, which is available under MedReleaf's profile on SEDAR at www.sedar.com.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6. Reliance on Subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Igor Gimelshtein, Chief Financial Officer of MedReleaf, is an executive officer of MedReleaf and is knowledgeable about the material change and this report. Mr. Gimelshtein can be contacted at 289-317-1004 or at igimelshtein@medreleaf.com.

Item 9. Date of Report

August 2, 2018